Teva Pharmaceutical Industries Ltd. ADR (TEVA) News
Filter TEVA News Items
TEVA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TEVA News Highlights
- TEVA's 30 day story count now stands at 23.
- Over the past 24 days, the trend for TEVA's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- The most mentioned tickers in articles about TEVA are TEL, RPRX and UBS.
Latest TEVA News From Around the Web
Below are the latest news stories about TEVA PHARMACEUTICAL INDUSTRIES LTD that investors may wish to consider to help them evaluate TEVA as an investment opportunity.
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease TreatmentPARSIPPANY, N.J., November 30, 2023--Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi (EURONEXT: SAN and NASDAQ: SNY). TEV '574 is currently in Phase 2b clinical trials for the treatment of ulcerative colitis and Crohn's disease, two types of inflammatory bowel disease. |
Teva Pharmaceutical upgraded to 'Buy' at UBSUBS upgraded Teva Pharmaceutical (TEVA) to Buy from Neutral and raised its price target on the stock to $13 per share. UBS sees Teva "uniquely positioned to undergo a significant transition" to a more brand-focused company. Yahoo Finance anchors Seana Smith and Diane King Hall break down UBS's call on Teva and the stock's recent gains. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. |
Roku upgraded, Lucid Group downgraded: Wall Street's top analyst callsRoku upgraded, Lucid Group downgraded: Wall Street's top analyst calls |
Teva Pharmaceutical: Long-Term Cash CowTeva Pharmaceutical is the leader in the global generic drugs market. |
Midday movers: Affirm, Amazon, and More(Updated - November 27, 2023 1:12 PM EST) |
Roku raised to Buy, YPF extends gains following upgrade: 4 big analyst picksWhile Teva's focus in recent years has been on stabilizing revenue and EBITDA, analysts expect future attention to turn toward Teva's attractive brand assets. This shift could allow investors to benefit from accelerated product launches and reduced pipeline risks. |
3 Resilient Stocks with Massive Potential to Boost Your WealthThese three stocks with massive potential can make patient investors fabuslously wealthy as they come roaring back to life. |
Teva to Present at the 6th Annual Evercore ISI HealthCONx ConferenceTEL AVIV, Israel, November 20, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023. The presentation will begin at 8:20 A.M. Eastern Time. |
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.PARSIPPANY, N.J. & TEL AVIV, Israel, November 17, 2023--Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generic version of Forteo®1, in the United States. Market availability of the product in the U.S. is expected in the coming weeks. |
50 Most Populated Countries in 2030In this article, we’ll list countries expected to be the most populated in 2030 and their population growth patterns. If you want to skip how the world’s population trends are changing, read 10 Most Populated Countries in 2030. Patterns in the World’s Population Growth As we approach 2030, it is crucial to understand the dynamics […] |